{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:35:41Z","timestamp":1791999341675,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s11882-008-0052-4","type":"journal-article","created":{"date-parts":[[2008,10,12]],"date-time":"2008-10-12T02:30:25Z","timestamp":1223778625000},"page":"323-330","source":"Crossref","is-referenced-by-count":21,"title":["Neuro-ophthalmic complications in giant cell arteritis"],"prefix":"10.1007","volume":"8","author":[{"given":"Frances A.","family":"Borg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria L. J.","family":"Salter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,11]]},"reference":[{"key":"52_CR1","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0161-6420(01)00574-7","volume":"108","author":"N.H. Liu","year":"2001","unstructured":"Liu NH, LaBree LD, Feldon SE, et al.: The epidemiology of giant cell arteritis. Ophthalmology 2001, 108:1145\u20131149.","journal-title":"Ophthalmology"},{"key":"52_CR2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/ard.2005.046912","volume":"65","author":"L. Smeeth","year":"2006","unstructured":"Smeeth L, Cook C, Hall AJ: Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990\u20132001. Ann Rheum Dis 2006, 65:1093\u20131098.","journal-title":"Ann Rheum Dis"},{"key":"52_CR3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.57.6.380","volume":"57","author":"O. Rauzy","year":"1998","unstructured":"Rauzy O, Fort M, Nourhashemi F, et al.: Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis. Ann Rheum Dis 1998, 57:380\u2013382.","journal-title":"Ann Rheum Dis"},{"key":"52_CR4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00005792-200009000-00001","volume":"79","author":"M.A. Gonzalez-Gay","year":"2000","unstructured":"Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al.: Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine 2000, 79:283\u2013292.","journal-title":"Medicine"},{"key":"52_CR5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.21075","volume":"53","author":"C. Salvarani","year":"2005","unstructured":"Salvarani C, Cimino L, Macchioni P, et al.: Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005, 53:293\u2013297.","journal-title":"Arthritis Rheum"},{"key":"52_CR6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/jnnp.2006.113787","volume":"78","author":"T. Loddenkemper","year":"2007","unstructured":"Loddenkemper T, Pankaj P, Katzan I, Plant GT: Risk factors for early visual deterioration in temporal arteritis. J Neurol Neurosurg Psychiatry 2007, 78:1255\u20131259.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"52_CR7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.md.0000119761.27564.c9","volume":"83","author":"G. Nesher","year":"2004","unstructured":"Nesher G, Berkun Y, Mates M, et al.: Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 2004, 83:114\u2013122.","journal-title":"Medicine"},{"key":"52_CR8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archopht.124.3.416","volume":"124","author":"A. Galor","year":"2006","unstructured":"Galor A, Lee MS: Slowly progressive vision loss in giant cell arteritis. Arch Ophthalmol 2006, 124:416\u2013418.","journal-title":"Arch Ophthalmol"},{"key":"52_CR9","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/archopht.124.6.922","volume":"124","author":"S. Cohen","year":"2006","unstructured":"Cohen S, Gardner F: Bilateral choroidal ischemia in giant cell arteritis. Arch Ophthalmol 2006, 124:922.","journal-title":"Arch Ophthalmol"},{"key":"52_CR10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s004170100310","volume":"239","author":"A.G. Lee","year":"2001","unstructured":"Lee AG, Tang RA, Feldon SE, et al.: Orbital presentations of giant cell arteritis. Graefe\u2019s Arch Clin Exp Ophthalmol 2001, 239:509\u2013513.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"52_CR11","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2005.01.036","volume":"112","author":"H. Danesh-Meyer","year":"2005","unstructured":"Danesh-Meyer H, Savino PJ, Gamble GG: Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005, 112:1098\u20131103.","journal-title":"Ophthalmology"},{"key":"52_CR12","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0161-6420(03)00228-8","volume":"110","author":"S.S. Hayreh","year":"2003","unstructured":"Hayreh SS, Zimmerman B: Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003, 110:1204\u20131215.","journal-title":"Ophthalmology"},{"key":"52_CR13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/rheumatology\/ken012","volume":"47","author":"D. Makkuni","year":"2008","unstructured":"Makkuni D, Bharadwaj A, Wolfe K, et al.: Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology (Oxford) 2008, 47:488\u2013490.","journal-title":"Rheumatology (Oxford)"},{"key":"52_CR14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jama.287.1.92","volume":"287","author":"G.W. Smetana","year":"2002","unstructured":"Smetana GW, Shmerling RH: Does this patient have temporal arteritis? JAMA 2002, 287:92\u2013101.","journal-title":"JAMA"},{"key":"52_CR15","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.11353","volume":"48","author":"D.M. Nuenninghoff","year":"2003","unstructured":"Nuenninghoff DM, Hunder GG, Christianson TJH, et al.: Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis. Arthritis Rheum 2003, 48:3522\u20133531.","journal-title":"Arthritis Rheum"},{"key":"52_CR16","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/1529-0131(199905)42:5<844::AID-ANR2>3.0.CO;2-M","volume":"42","author":"C.M. Weyand","year":"1999","unstructured":"Weyand CM, Goronzy JJ: Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999, 42:844\u2013853.","journal-title":"Arthritis Rheum"},{"key":"52_CR17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.1780400105","volume":"40","author":"C.M. Weyand","year":"1997","unstructured":"Weyand CM, Tetzlaff N, Bjornsson J, et al.: Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997, 40:19\u201326.","journal-title":"Arthritis Rheum"},{"key":"52_CR18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/rheumatology\/keh058","volume":"43","author":"J. Hernandez-Rodriguez","year":"2004","unstructured":"Hernandez-Rodriguez J, Segarra M, Vilardell C, et al.: Tissue production of pro-inflammatory cytokines (IL-1\u03b2\u03b1, TNF-\u03b1 and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 2004, 43:294\u2013301.","journal-title":"Rheumatology"},{"key":"52_CR19","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1161\/01.CIR.0000066907.83923.32","volume":"107","author":"J. Hernandez-Rodriguez","year":"2003","unstructured":"Hernandez-Rodriguez J, Segarra M, Vilardell C, et al.: Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis. Circulation 2003, 107:2428\u20132434.","journal-title":"Circulation"},{"key":"52_CR20","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/ard.2005.042770","volume":"65","author":"A. Mahr","year":"2006","unstructured":"Mahr A, Saba M, Kambouchner M, et al.: Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis 2006, 65:826\u2013828.","journal-title":"Ann Rheum Dis"},{"key":"52_CR21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0002-9394(99)00101-4","volume":"128","author":"L.R. Boyev","year":"1999","unstructured":"Boyev LR, Miller NR, Green WR: Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol 1999, 128:211\u2013215.","journal-title":"Am J Ophthalmol"},{"key":"52_CR22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00041327-200020030-00011","volume":"20","author":"H.V. Danesh-Meyer","year":"2000","unstructured":"Danesh-Meyer HV, Savino PJ, Eagle RC, et al.: Low diagnostic yield with second biopsies in suspected giant cell arteritis. J neuro-ophthalmol 2000, 20:213\u2013215.","journal-title":"J neuro-ophthalmol"},{"key":"52_CR23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/jcp.53.2.131","volume":"53","author":"A. Chakrabarty","year":"2000","unstructured":"Chakrabarty A, Franks AJ: Temporal artery biopsy: is there any value in examining biopsies at multiple levels? J Clin Pathol 2000, 53:131\u2013136.","journal-title":"J Clin Pathol"},{"key":"52_CR24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.7326\/0003-4819-120-12-199406150-00003","volume":"120","author":"A.A. Achkar","year":"1994","unstructured":"Achkar AA, Lie JT, Hunder GG, et al.: How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994, 120:987\u2013992.","journal-title":"Ann Intern Med"},{"key":"52_CR25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/bjo.86.5.530","volume":"86","author":"N. Ray-Chaudhuri","year":"2002","unstructured":"Ray-Chaudhuri N, Ah Kine D, Tijani SO, et al.: Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol 2002, 86:530\u2013532.","journal-title":"Br J Ophthalmol"},{"key":"52_CR26","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJM199711063371902","volume":"337","author":"W.A. Schmidt","year":"1997","unstructured":"Schmidt WA, Kraft HE, Vorpahl K, et al.: Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997, 337:1336\u20131342.","journal-title":"N Engl J Med"},{"key":"52_CR27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/sj.eye.6700350","volume":"17","author":"H. Murgatroyd","year":"2003","unstructured":"Murgatroyd H, Nimmo M, Evans A, MacEwen C: The use of ultrasound as an aid in the diagnosis of giant cell arteritis: a pilot study comparing histological features with ultrasound findings. Eye 2003, 17:415\u2013419.","journal-title":"Eye"},{"key":"52_CR28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.7326\/0003-4819-142-5-200503010-00011","volume":"142","author":"F.B. Karassa","year":"2005","unstructured":"Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JPA: Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med 2005, 142:359\u2013369.","journal-title":"Ann Intern Med"},{"key":"52_CR29","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/archinte.161.7.1003","volume":"161","author":"A. Turlakow","year":"2001","unstructured":"Turlakow A, Yeung HWD, Pui J, et al.: Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 2001, 161:1003\u20131007.","journal-title":"Arch Intern Med"},{"key":"52_CR30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/art.21699","volume":"55","author":"D. Blockmans","year":"2006","unstructured":"Blockmans D, de Ceuninck L, Vanderschueren S, et al.: Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006, 55:131\u2013137.","journal-title":"Arthritis Rheum"},{"key":"52_CR31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/rheumatology\/keh513","volume":"44","author":"J. Narvaez","year":"2005","unstructured":"Narvaez J, Narvaez JJ, Nolla JM, et al.: Giant cell arteritis and polymyalgia rheumatica: usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology 2005, 44:479\u2013483.","journal-title":"Rheumatology"},{"key":"52_CR32","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3174\/ajnr.A0638","volume":"28","author":"T.A. Bley","year":"2007","unstructured":"Bley TA, Uhl M, Carew J, et al.: Diagnostic value of high-resolution MR imaging in giant cell arteritis. Am J Neuroradiol 2007, 28:1722\u20131727.","journal-title":"Am J Neuroradiol"},{"key":"52_CR33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/rheumatology\/kem283","volume":"47","author":"T.A. Bley","year":"2008","unstructured":"Bley TA, Markl M, Schlep M, et al.: Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment. Rheumatology 2008, 47:65\u201367.","journal-title":"Rheumatology"},{"key":"52_CR34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1034\/j.1600-0420.2002.800402.x","volume":"80","author":"S.S. Heyreh","year":"2002","unstructured":"Heyreh SS, Zimmerman B, Kardon RH: Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002, 80:353\u2013367.","journal-title":"Acta Ophthalmol Scand"},{"key":"52_CR35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","volume":"49","author":"A. Proven","year":"2003","unstructured":"Proven A, Gabriel SK, Orces C, et al.: Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003, 49:703\u2013708.","journal-title":"Arthritis Rheum"},{"key":"52_CR36","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1136\/bjo.85.9.1061","volume":"85","author":"C.C.K. Chan","year":"2001","unstructured":"Chan CCK, Paine M, O\u2019Day J: Steroid management in giant cell arteritis. Br J Ophthalmol 2001, 85:1061\u20131064.","journal-title":"Br J Ophthalmol"},{"key":"52_CR37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0161-6420(02)01775-X","volume":"110","author":"R. Faroozan","year":"2003","unstructured":"Faroozan R, Deramo VA, Buono LM, et al.: Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 2003, 110:539\u2013542.","journal-title":"Ophthalmology"},{"key":"52_CR38","first-page":"1484","volume":"27","author":"P. Chevalet","year":"2000","unstructured":"Chevalet P, Barrier J-H, Pottier P, et al.: A randomized, multicenter, controlled trial using intravenous pulses of Methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000, 27:1484\u20131491.","journal-title":"J Rheumatol"},{"key":"52_CR39","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","volume":"54","author":"M. Mazlumzadeh","year":"2006","unstructured":"Mazlumzadeh M, Hunder GG, Easley KA, et al.: Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids. Arthritis Rheum 2006, 54:3310\u20133318.","journal-title":"Arthritis Rheum"},{"key":"52_CR40","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.20171","volume":"50","author":"G. Nesher","year":"2004","unstructured":"Nesher G, Berkun Y, Mates M, et al.: Low-dose aspirin and prevention of cranial ischaemic complications in giant cell arteritis. Arthritis Rheum 2004, 50:1332\u20131337.","journal-title":"Arthritis Rheum"},{"key":"52_CR41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/art.10071","volume":"46","author":"C.M. Weyand","year":"2002","unstructured":"Weyand CM, Kaiser M, Yang H, et al.: Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002, 46:457\u2013466.","journal-title":"Arthritis Rheum"},{"key":"52_CR42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","volume":"134","author":"J.A. Jover","year":"2001","unstructured":"Jover JA, Hernandez-Garcia C, Morado IC, et al.: Combined treatment of giant cell arteritis with methotrexate and prednisone. Ann Intern Med 2001, 134:106\u2013114.","journal-title":"Ann Intern Med"},{"key":"52_CR43","first-page":"495","volume":"19","author":"R.F. Spiera","year":"2001","unstructured":"Spiera RF, Mitnick HJ, Kupersmith M, et al.: A prospective double-blind randomized placebo controlled trial of methotrexate in the treatment of giant cella arteritis. Clin Exp Rheumatol 2001, 19:495\u2013501.","journal-title":"Clin Exp Rheumatol"},{"key":"52_CR44","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","volume":"46","author":"G.S. Hoffman","year":"2002","unstructured":"Hoffman GS, Cid MC, Helklmann DB, et al.: A multicentre randomized double blind placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002, 46:1309\u20131318.","journal-title":"Arthritis Rheum"},{"key":"52_CR45","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","volume":"56","author":"A.D. Mahr","year":"2007","unstructured":"Mahr AD, Jover JA, Spiera RF, et al.: Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007, 56:2789\u20132797.","journal-title":"Arthritis Rheum"},{"key":"52_CR46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","volume":"45","author":"M. Silva De","year":"1986","unstructured":"De Silva M, Hazleman BL: Azathioprine in giant cell arteritis\/ polymyalgia rheumatica: a double blind study. Ann Rheum Dis 1986, 45:136\u2013138.","journal-title":"Ann Rheum Dis"},{"key":"52_CR47","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1002\/1529-0131(200112)44:12<2933::AID-ART482>3.0.CO;2-Y","volume":"44","author":"F. Cantini","year":"2001","unstructured":"Cantini F, Niccoli L, Salvarani C, et al.: Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001, 44:2933\u20132935.","journal-title":"Arthritis Rheum"},{"key":"52_CR48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/ard.62.4.373","volume":"62","author":"A.L. Tan","year":"2003","unstructured":"Tan AL, Holdsworth J, Pease C, et al.: Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003, 62:373\u2013374.","journal-title":"Ann Rheum Dis"},{"key":"52_CR49","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/ard.62.11.1116","volume":"62","author":"A.P. Andonopoulos","year":"2003","unstructured":"Andonopoulos AP, Meimaris N, Daoussis D, et al.: Experience with infliximab (anti-TNF-\u03b1 monoclonal antibody) as monotherapy for giant cell arteritis. Ann Rheum Dis 2003, 62:1116.","journal-title":"Ann Rheum Dis"},{"key":"52_CR50","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","volume":"146","author":"C. Salvarani","year":"2007","unstructured":"Salvarani C, Macchioni P, Manzini C, et al.: Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica. Ann Intern Med 2007, 146:631\u2013639.","journal-title":"Ann Intern Med"},{"key":"52_CR51","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","volume":"146","author":"G.S. Hoffman","year":"2007","unstructured":"Hoffman GS, Cid MC, Rendt-Zagar KE, et al.: Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Intern Med 2007, 146:621\u2013630.","journal-title":"Ann Intern Med"},{"key":"52_CR52","doi-asserted-by":"crossref","unstructured":"Martinez-Taboada VM, Rodriguez-Valverde V, Carre\u00f1o L, et al.: A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2007 (Epub ahead of print).","DOI":"10.1136\/ard.2007.082115"},{"key":"52_CR53","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/ard.2005.036533","volume":"64","author":"A. Bhatia","year":"2005","unstructured":"Bhatia A, Ell PJ, Edwards JCW: Anti-CD20 monoclonal antibody (Rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005, 64:1099\u20131100.","journal-title":"Ann Rheum Dis"},{"key":"52_CR54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/bjo.85.3.327","volume":"85","author":"M.M. Brown","year":"2001","unstructured":"Brown MM, Brown GC, Sharma S, et al.: Utility values associated with blindness in an adult population. Br J Ophthalmol 2001, 85:327\u2013331.","journal-title":"Br J Ophthalmol"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-008-0052-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-008-0052-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-008-0052-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:42:18Z","timestamp":1559432538000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-008-0052-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1007\/s11882-008-0052-4","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}